Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation

PLoS Pathogens

Volumn 12, Issue 6, 2016, Pages

  Abdel Mohsen, Mohamed ^a,b   Chavez, Leonard ^a   Tandon, Ravi ^c   Chew, Glen M ^d   Deng, Xutao ^a   Danesh, Ali ^a,b   Keating, Sheila ^a   Lanteri, Marion ^a   Samuels, Michael L ^e   Hoh, Rebecca ^b   Sacha, Jonah B ^f,g   Norris, Philip J ^a,b   Niki, Toshiro ^h,i   Shikuma, Cecilia M ^d   Hirashima, Mitsuomi ^h,i   Deeks, Steven G ^b   Ndhlovu, Lishomwa C ^d   Pillai, Satish K ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

^d UNIVERSITY OF HAWAII   (United States)

^e RainDance Technologies   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h GalPharma Co   (Japan)

ⁱ KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BARRIER TO AUTOINTEGRATION FACTOR; BRYOSTATIN; DNA METHYLTRANSFERASE 1; ECALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 4; GALECTIN 7; GALECTIN 8; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; PANOBINOSTAT; PROTEIN P21; ROMIDEPSIN; TRANSCRIPTION FACTOR EZH2; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GALECTIN; LGALS9 PROTEIN, HUMAN; TRANSCRIPTOME;

ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DEGLYCOSYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; T CELL DEPLETION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; WESTERN BLOTTING; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS ACTIVATION;

ANTI-HIV AGENTS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GALECTINS; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRANSCRIPTOME; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84978823390     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005677     Document Type: Article

References (80)

1. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science278: 1291–1295. 9360926
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science278: 1295–1300. 9360927
3. Butler KM, Gavin P, Coughlan S, Rochford A, Mc Donagh S, et al. (2015) Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr Infect Dis J34: e48–51. doi: 10.1097/INF.000000000000057025742088
4. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, et al. (2014) Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med161: 319–327. doi: 10.7326/M14-102725047577
5. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, et al. (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog9: e1003211. doi: 10.1371/journal.ppat.100321123516360
6. Siliciano JD, Siliciano RF, (2013) HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS8: 318–325. doi: 10.1097/COH.0b013e328361eaca23698561
7. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, et al. (2014) Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog10: e1004473. doi: 10.1371/journal.ppat.100447325393648
8. Olesen R, Vigano S, Rasmussen T, Sogaard OS, Ouyang Z, et al. (2015) Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J Virol.
9. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, et al. (2014) A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis58: 883–890. doi: 10.1093/cid/cit81324336828
10. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, et al. (2014) HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis210: 728–735. doi: 10.1093/infdis/jiu15524620025
11. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature487: 482–485. doi: 10.1038/nature1128622837004
12. Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, et al. (2015) Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV2: e520–529. doi: 10.1016/S2352-3018(15)00226-X26614966
13. Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, et al. (2015) The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathog11: e1005142. doi: 10.1371/journal.ppat.100514226379282
14. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, et al. (2015) Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest125: 1901–1912. doi: 10.1172/JCI8014225822022
15. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ, (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell75: 805–816. 8242751
16. Chen H, Li C, Huang J, Cung T, Seiss K, et al. (2011) CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest121: 1549–1560. doi: 10.1172/JCI4453921403397
17. Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, et al. (2015) Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS29: 411–420. doi: 10.1097/QAD.000000000000057225602681
18. Kurose Y, Wada J, Kanzaki M, Teshigawara S, Nakatsuka A, et al. (2013) Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrol14: 23. doi: 10.1186/1471-2369-14-2323339460
19. Baba M, Wada J, Eguchi J, Hashimoto I, Okada T, et al. (2005) Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms. J Am Soc Nephrol16: 3222–3234. 16177004
20. Elahi S, Niki T, Hirashima M, Horton H, (2012) Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood119: 4192–4204. doi: 10.1182/blood-2011-11-38958522438246
21. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, et al. (1994) Galectins: a family of animal beta-galactoside-binding lectins. Cell76: 597–598. 8124704
22. Kasai K, Hirabayashi J, (1996) Galectins: a family of animal lectins that decipher glycocodes. J Biochem119: 1–8. 8907168
23. Cooper DN, (2002) Galectinomics: finding themes in complexity. Biochim Biophys Acta1572: 209–231. 12223271
24. Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, et al. (2010) Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog6: e1000882. doi: 10.1371/journal.ppat.100088220463811
25. Tandon R, Chew GM, Byron MM, Borrow P, Niki T, et al. (2014) Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers. AIDS Res Hum Retroviruses30: 654–664. doi: 10.1089/AID.2014.000424786365
26. Jost S, Moreno-Nieves UY, Garcia-Beltran WF, Rands K, Reardon J, et al. (2013) Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection. Retrovirology10: 74. doi: 10.1186/1742-4690-10-7423866914
27. Wang F, He W, Yuan J, Wu K, Zhou H, et al. (2008) Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol19: 12–19. doi: 10.1016/j.trim.2008.01.00818346632
28. Seki M, Sakata KM, Oomizu S, Arikawa T, Sakata A, et al. (2007) Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum56: 3968–3976. 18050192
29. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, et al. (2007) Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med176: 27–35. 17446336
30. Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, et al. (2010) Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res8: 994–1001. doi: 10.1158/1541-7786.MCR-10-004020571063
31. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, et al. (2008) Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology18: 735–744. doi: 10.1093/glycob/cwn06218579572
32. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, et al. (2012) Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood119: 3064–3072. doi: 10.1182/blood-2011-06-36032122323453
33. Mishra R, Grzybek M, Niki T, Hirashima M, Simons K, (2010) Galectin-9 trafficking regulates apical-basal polarity in Madin-Darby canine kidney epithelial cells. Proc Natl Acad Sci U S A107: 17633–17638. doi: 10.1073/pnas.101242410720861448
34. Chavez L, Kauder S, Verdin E, (2011) In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. Methods53: 47–53. doi: 10.1016/j.ymeth.2010.05.00920670606
35. Jordan A, Bisgrove D, Verdin E, (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J22: 1868–1877. 12682019
36. Chan JK, Bhattacharyya D, Lassen KG, Ruelas D, Greene WC, (2013) Calcium/calcineurin synergizes with prostratin to promote NF-kappaB dependent activation of latent HIV. PLoS One8: e77749. doi: 10.1371/journal.pone.007774924204950
37. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, et al. (2014) Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog10: e1004071. doi: 10.1371/journal.ppat.100407124722454
38. DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, et al. (2012) Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem4: 705–710. doi: 10.1038/nchem.139522914190
39. Perez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, et al. (2010) Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res8: 418–429. 20636281
40. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, et al. (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood98: 3006–3015. 11698284
41. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One4: e6093. doi: 10.1371/journal.pone.000609319564922
42. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, et al. (2004) Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem279: 42008–42017. 15284245
43. Jiang G, Mendes EA, Kaiser P, Wong DP, Tang Y, et al. (2015) Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog11: e1005066. doi: 10.1371/journal.ppat.100506626225771
44. Li Z, Guo J, Wu Y, Zhou Q, (2013) The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res41: 277–287. doi: 10.1093/nar/gks97623087374
45. Zhu J, Gaiha GD, John SP, Pertel T, Chin CR, et al. (2012) Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep2: 807–816. doi: 10.1016/j.celrep.2012.09.00823041316
46. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, et al. (2014) Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV1: e13–21. doi: 10.1016/S2352-3018(14)70014-126423811
47. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, et al. (2015) Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother59: 5984–5991. doi: 10.1128/AAC.01077-1526169416
48. Bliss CI, (1939) The toxicity of poisons applied jointlyAnn Appl Biol26: 585–615. Find this article online.
49. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, et al. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol6: 1245–1252. 16286920
50. Bi S, Hong PW, Lee B, Baum LG, (2011) Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A108: 10650–10655. doi: 10.1073/pnas.101795410821670307
51. Wu C, Thalhamer T, Franca RF, Xiao S, Wang C, et al. (2014) Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity41: 270–282. doi: 10.1016/j.immuni.2014.06.01125065622
52. Lecossier D, Bouchonnet F, Clavel F, Hance AJ, (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science300: 1112. 12750511
53. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol11: 435–442. 15098018
54. Keating SM, Hanson D, Lebedeva M, Laeyendecker O, Ali-Napo NL, et al. (2012) Lower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation. J Clin Microbiol50: 3968–3976. doi: 10.1128/JCM.01454-1223035182
55. Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, et al. (2013) Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog9: e1003347. doi: 10.1371/journal.ppat.100334723671416
56. Lanteri M, Giordanengo V, Hiraoka N, Fuzibet JG, Auberger P, et al. (2003) Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology13: 909–918. 12925577
57. Ardman B, Sikorski MA, Settles M, Staunton DE, (1990) Human immunodeficiency virus type 1-infected individuals make autoantibodies that bind to CD43 on normal thymic lymphocytes. J Exp Med172: 1151–1158. 1976735
58. Giordanengo V, Limouse M, Desroys du Roure L, Cottalorda J, Doglio A, et al. (1995) Autoantibodies directed against CD43 molecules with an altered glycosylation status on human immunodeficiency virus type 1 (HIV-1)-infected CEM cells are found in all HIV-1+ individuals. Blood86: 2302–2311. 7662977
59. Bi S, Earl LA, Jacobs L, Baum LG, (2008) Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J Biol Chem283: 12248–12258. doi: 10.1074/jbc.M80052320018258591
60. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, et al. (2012) Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A109: 3035–3040. doi: 10.1073/pnas.111157310922315404
61. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med9: 1404–1407. 14528300
62. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, et al. (2010) Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS24: 2451–2460. doi: 10.1097/QAD.0b013e32833ef7bb20827162
63. Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, et al. (2014) The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. J Virol88: 10803–10812. doi: 10.1128/JVI.00320-1425008921
64. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, et al. (2008) Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol181: 7660–7669. 19017954
65. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med15: 893–900. doi: 10.1038/nm.197219543283
66. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, et al. (2008) Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol127: 78–88. doi: 10.1016/j.clim.2008.01.00618282810
67. Wang F, He W, Zhou H, Yuan J, Wu K, et al. (2007) The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol250: 68–74. doi: 10.1016/j.cellimm.2008.01.00618353298
68. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, et al. (2014) Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog10: e1004287. doi: 10.1371/journal.ppat.100428725122219
69. Wang C, Abdel-Mohsen M, Strain MC, Lada SM, Yukl S, et al. (2014) Decreased HIV type 1 transcription in CCR5-Delta32 heterozygotes during suppressive antiretroviral therapy. J Infect Dis210: 1838–1843. doi: 10.1093/infdis/jiu33824935955
70. Nishi N, Abe A, Iwaki J, Yoshida H, Itoh A, et al. (2008) Functional and structural bases of a cysteine-less mutant as a long-lasting substitute for galectin-1. Glycobiology18: 1065–1073. doi: 10.1093/glycob/cwn08918796645
71. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, et al. (2005) Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett579: 2058–2064. 15811318
72. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, et al. (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc7: 562–578. doi: 10.1038/nprot.2012.01622383036
73. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol3: RESEARCH0034.
74. Stopak K, de Noronha C, Yonemoto W, Greene WC, (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell12: 591–601. 14527406
75. Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S, (1989) Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A86: 1624–1628. 2922401
76. Fouchier RA, Simon JH, Jaffe AB, Malim MH, (1996) Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol70: 8263–8269. 8970945
77. Simon JH, Fouchier RA, Southerling TE, Guerra CB, Grant CK, et al. (1997) The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol71: 5259–5267. 9188594
78. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH, (1995) Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol69: 4166–4172. 7769676
79. Vandergeeten C, Fromentin R, Merlini E, Lawani MB, DaFonseca S, et al. (2014) Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol88: 12385–12396. doi: 10.1128/JVI.00609-1425122785
80. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I, (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res125: 279–284. 11682119